Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus paclitaxel vs placebo plus paclitaxel in advanced gastric cancer after first-line failure
CTR20140637Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Started Oct 2014; status: completed.
02
Drugs
olaparib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20140637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140637.